April 5, 2021 -- Inscripta has shipped its first Onyx platform for benchtop genome engineering and also closed $150 million in financing.
The Onyx platform is a benchtop system for scalable digital genome engineering and consists of a benchtop instrument, consumables, software, and assays. The fully automated CRISPR workflow allows parallel, trackable editing of single cells, the company said. The first organization to receive the Onyx platform is GeneMill, a synthetic biology foundry at the University of Liverpool.
Funds from the $150 million series E financing round will be used to create CRISPR-based technology from the company's intellectual property portfolio, which includes nearly 100 issued U.S. patents, according to Inscripta. The financing round was led by Fidelity.